Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

21 May 2009

Generic products of immunosuppressive drugs according to incoming new emea guideline

P Kunicki

Ann Transplant 2009; 14(1): 75-76 :: ID: 880478

Abstract

Note for Guidance on the Investigation of Bioavailability and Bioequivalence,
CPMP/EWP/QWP/1401/98, EMEA, 26 July 2001, presents general rules for
generic drugs registration. For majority of generally acting drugs - simple
single-dose, 2-period, 2-sequence, crossover bioequivalence study in young
healthy volunteers in fasting state is usually performed. The decision regarding bioequivalence is based on 90% confidence intervals for AUC and Cmax ratios (test/reference) being within 80-125% for log-transformed data. For many years, such approach was criticized as inappropriate for some drugs with narrow therapeutic range, also called as "critical dose drugs". As a result of scientific debate, a new EMEA Guideline on the Investigation of Bioequivalence is coming into operation in 2009. The class of narrow therapeutic index drugs (NTDIs) is formally created for agents with steep concentration response relationship for efficacy and/or toxicity. These drugs require dosage individualisation based on therapeutic drug monitoring or titrated according to clinical response as a high risk of serious clinical consequences is expected in the event of too low or too high concentrations. All primary immunosuppressive drugs (cyclosporine, tacrolimus, sirolimus, and everolimus) can be easily and undoubtedly considered as NTDIs. However, the classification as NTDI must be made individually for particular drug. In these specific cases, the acceptance interval for AUC and Cmax ratios may need to be tightened to 90-111%. Moreover, in individual cases additional or alternative requirements might be set. Described standards oblige Registration Agencies to obey more restrictive rules for generic products of immunosuppressive drugs.

Add Comment 0 Comments

In Press

12 Feb 2024 : Original article  

No Prognostic Impact of Graft-to-Recipient Weight Ratio on Hepatocellular Carcinoma Recurrence Following Li...

Ann Transplant In Press; DOI: 10.12659/AOT.942767  

21 Feb 2024 : Original article  

Use of LCP-Tacrolimus (LCPT) in Kidney Transplantation: A Delphi Consensus Survey of Expert Clinicians

Ann Transplant In Press; DOI: 10.12659/AOT.943498  

Most Viewed Current Articles

05 Apr 2022 : Original article  

Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation

DOI :10.12659/AOT.935604

Ann Transplant 2022; 27:e935604

12 Jan 2022 : Original article  

Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...

DOI :10.12659/AOT.934738

Ann Transplant 2022; 27:e934738

22 Nov 2022 : Original article  

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...

DOI :10.12659/AOT.937988

Ann Transplant 2022; 27:e937988

15 Mar 2022 : Case report  

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358